Tonix Pharmaceuticals
February 10, 2025
Plymouth
CNS/Neurological
Tonix is a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates. Tonix’s lead program, TNX-102 SL, is a U.S. FDA Fast-Track designated product candidate for the management of fibromyalgia and for which an NDA was recently submitted to FDA based on two statistically significant Phase 3 studies. Tonix markets Zembrace® SymTouch® and Tosymra®, each indicated for the treatment of acute migraine with or without aura in adults.
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}